Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › ABVX

Abivax

ABVX Lead: Phase 3 1 Biotech Distilled article ↓ 18 filings & releases ↓ Cash €517M (Dec 31, 2025) ↓ 1 verdict ↓
Immunology Small Molecule

Market cap $7.50B 87.5M shares (vendor count, Nov 7, 2026) × $85.73 close Nov 6, 2026 · share count from the market-data vendor, not the SEC cover page

Most recent annual filing: 2026-03-23

Catalyst timeline

8 trackedQuarter catalyst calendar →
  1. Obefazimod combination/miR-124 follow-on corporate updateYear-end 2026 (guided)Obefazimod combination/miR-124 follow-on corporate update, Year-end 2026 (guided), routine
  2. Obefazimod NDA filinglate 4Q 2026Obefazimod NDA filing, late 4Q 2026, material
  3. Obefazimod FDA decision~Jan–Mar 2027Obefazimod FDA decision, ~Jan–Mar 2027, major
  4. Roche afimkibart AMETRINE-1 readoutJan 30, 2027Roche afimkibart AMETRINE-1 readout, Jan 30, 2027, notable
  5. Obefazimod Crohn's disease Ph2b toplineMid-2027 (guided)Obefazimod Crohn's disease Ph2b topline, Mid-2027 (guided), material
  6. Obefazimod PDUFA date~Jul–Dec 2027Obefazimod PDUFA date, ~Jul–Dec 2027, material
  7. J&J icotrokinra UC readoutJan 14, 2028J&J icotrokinra UC readout, Jan 14, 2028, notable
  8. Sanofi/Teva duvakitug SUNSCAPE-1 readoutMay 9, 2028Sanofi/Teva duvakitug SUNSCAPE-1 readout, May 9, 2028, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (2 active programs)

Technology platforms

miR-124

Proprietary small molecule platform targeting miR-124 enhancers; focus on generating new drug candidates for chronic inflammatory diseases. Includes a proprietary small molecule library of miR-124 enhancers.

Targets: miR-124

Capital (as filed)

Cash
€517M cash and cash equivalents · Dec 31, 2025 (20-F)
Operating cash flow
−€40.3M annual ÷ 4, year to Dec 31, 2025 (20-F)
As stated in coverage
€1.33B cash, runway into Q4 2029 per the deep dive of Oct 13, 2026 — the company's own words as read there, not the filed figure; stated in EUR

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (1)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (1 call)

Every verdict Biotech Distilled has published on Abivax, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-10-14 Watch Abivax (ABVX) - Scientific Deep Dive for Obefazimod (ABX464) and Pipeline Products Strong Phase 3 efficacy but all six malignancies on the 50 mg dose and a label decision a year away make the current ~$6.2B EV insufficient discount to buy.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (18)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Nov 2, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

5 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)